GSK’s ViiV Healthcare reports CROWN endpoint: GSK stock pre-market at EUR 20.86, minus 0.62 percent
Published on 10/08/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK’s majority-owned ViiV Healthcare said on October 6 that its phase IIIb CROWN study met its primary endpoint, with long-acting Cabenuva showing superior viral suppression to daily oral therapy after six months in people with detectable HIV-1 virus. At 8:14 a.m. CEST on October 8, GSK stock was at EUR 20.86 pre-market at Lang & Schwarz, down 0.62 percent versus the Lang & Schwarz close of EUR 20.99 on October 7. The company-specific update was published by BioSpace.
GSK stock before the Xetra open
The Lang & Schwarz indication stood at EUR 20.86 at 8:14 a.m. CEST. The bid was EUR 20.81 and the ask was EUR 20.91. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of GSK stock.
Details of the HIV study
ViiV said CROWN was an international, randomized, open-label study involving approximately 326 adults and adolescents across eight countries and 85 sites. The trial evaluated whether participants with detectable virus and a history of daily oral antiretroviral therapy could directly start cabotegravir plus rilpivirine, administered six times a year, and achieve viral suppression. The use of the combination in people with detectable viremia remains investigational and has not been approved by regulatory authorities, according to the BioSpace report.
Next regulatory step
ViiV said the CROWN findings will be shared with health authorities for regulatory review, while full results are planned for presentation at an upcoming scientific meeting. Cabenuva is already approved in the United States and other markets for adults and adolescents who are virologically suppressed on a stable antiretroviral regimen and have no known or suspected resistance to cabotegravir or rilpivirine, the company said.
